The Power of Collaboration in Drug Development: Interview with: Professor Michel Goldman, Executive Director, Innovative Medicines Initiative (IMI), a speaker at the marcus evans Evolution Summit 2012, on how public-private partnerships can advance the field of drug development.

1. The Power of Collaboration
in Drug Development
Universities are having a hard time also make the dialogue easier and
convincing large pharma companies to prevent some conflict of interest issues.
take their research findings on board,
and they may underestimate the efforts U n t i l r e c e nt l y , c o m pan i e s w e r e
that remain to be made. On the negotiating agreements with universities
pharmaceutical company side, there are and partners in a way that was very
business and regulatory considerations unidirectional. Open innovation is more
that are preventing potentially useful bidirectional, which means that partners
com pon en ts from be i n g fur th er outside industry will also benefit from
developed. the expertise of companies for their own
purposes.
PPPs can address many of the
bottlenecks in clinical research and the Any final comments?
Interview with: Professor Michel difficulties in translating basic
Goldman, Executive Director, discoveries into pharmaceutical The experience gained from the
Innovative Medicines Initiative products. Innovative Medicines Initiatives and
(IMI) other public-private endeavours clearly
What opportunities does the public- demonstrate that PPP can be
private model present to instrumental to address the major
The only way to address major public pharmaceutical companies? What public health needs that human
health needs is through public-private does collaboration help them mankind is facing. However, to take full
partnerships (PPPs), according to achieve? advantage of PPPs, further changes in
Professor Michel Goldman, Executive mindsets and culture will be necessary
Director, Innovative Medicines Initiative Companies are targeting similar disease to bridge the world of industry and
(IMI). With the complex scientific, areas and producing similar products, academia and make collaborations as
business and regulatory hurdles facing and investing resources and gathering fruitful as possible.
both the public and private sectors, only data that are not shared. The same
PPPs can pool the knowledge and failures may have been repeated in
expertise required to move the field of several companies. Some companies
drug development forward. have now realised the benefits of inter-
company collaboration in pre -
A speaker at the upcoming marcus competitive or non-competitive
evans Evolution Summit 2012, in research. Indeed, companies can Public-private
Munich, Germany, 14 - 16 October, compete in the marketplace but agree
Professor Goldman turns the spotlight
on PPPs and discusses why there is a
to work together on a project to
mutualise risks and investments.
partnerships
need to bridge the world of industry and
academia in clinical trials.
However, even those collaborations may
not provide them with the knowledge
can address
How can PPPs accelerate drug
that academia could.
many of the
development and time to market? The value of collaboration in this field is
in sharing clinical data from successes bottlenecks in
Pharmaceutical companies and and failures. Combining data from
academia are facing a number of
hurdles along the value chain, from
different clinical trials allows them to
eliminate a number of pre-clinical
clinical research
basic discovery of a potential models. For rare diseases, it gives them
therapeutic target until the access to patient cohorts. If companies
commercialisation of the drug. approach regulators through PPPs, it will

2. About the Evolution Summit 2012
The Pharma Network –
marcus evans Summits group
This unique forum will take place at the Hotel Four Seasons Kempinkski, Munich,
delivers peer-to-peer information
Germany, 14 - 16 October 2012. Offering much more than any conference, seminar
on strategic matters, professional
or trade show, this exclusive meeting will bring together esteemed industry thought
trends and breakthrough
leaders and solution providers to a highly focused and interactive networking event.
innovations.
The Summit includes presentations on pharmaceutical innovation, maximising
clinical resources and delivering medical value, and reshaping R&D strategies.
www.evolution-summit.com
Contact
Please note that the Summit is a
Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits
closed business event and the
Division
number of participants strictly
limited.
Tel: + 357 22 849 313
Email: press@marcusevanscy.com
For more information please send an email to info@marcusevanscy.com
All rights reserved. The above content may be republished or reproduced. Kindly
inform us by sending an email to press@marcusevanscy.com
About marcus evans Summits
marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss
strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to
individually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.
For more information, please visit: www.marcusevans.com
Upcoming Events
Discovery Summit (Europe) - www.discovery-summit.com
Discovery Summit (North America) - www.thediscoverysummit.com
Evolution Summit (North America) - www.evolutionsummit.com.com
To view the web version of this interview, please click here: www.evolution-summit.com/MichelGoldman